~~U.S. SECURITIES~~UNITED ~~AND EXCHANGE COMMISSION~~STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

~~FORM~~ Form 10-Q

~~☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15~~(d)Mark ~~OF THE SECURITIES EXCHANGE ACT OF 1934~~One)

For the quarterly period ended February 28, 2019

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

	For the quarterly period ended May 31, 2019

or

¨	TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

	For the transition period from _________________ to _________________

~~☐ TRANSITION~~Commission ~~REPORT~~File ~~PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934~~Number 333-154989

~~For the~~ENTEST ~~transition~~GROUP, ~~period~~INC. ~~from~~(Exact name of registrant as specified in its charter)

Commission File No. 333-154989

Nevada		26-3431263
(State or other jurisdiction of incorporation or organization)		(IRS Employer Identification No.)

~~ENTEST~~No. ~~GROUP,~~911 ~~INC.~~Bao’an ~~(Exact~~Book ~~name~~City ofXinqiao ~~small~~Street ~~business~~Central ~~issuer~~Road, asBao’an ~~specified~~District, inShenzhen, ~~its~~China ~~charter~~(Address of principal executive offices) (Zip Code)

Nevada	26-3431263
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

86-13709631109

~~No. 911 Bao~~(Registrant’ans ~~Book~~telephone ~~City~~ number, including area code)

~~Xinqiao Street Central Road, Bao’an District, Shenzhen, China~~N/A

(~~Address of Principal Executive Offices) 86 -13709631109 (Issuer’s telephone number) (~~Former name, former address and former fiscal year, if changed since last report)

~~Indicate by~~Securities ~~check~~registered ~~mark~~pursuant ~~whether the registrant (1) has filed all reports required~~ to ~~be filed by~~ Section ~~13 or 15~~12(db) of the ~~Securities Exchange~~ Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐:

~~Indicate by~~Title ~~check mark whether the registrant has submitted electronically every Interactive Date File required to be submitted pursuant to Rule 405~~ of ~~Regulation~~each ~~S-T~~class ~~(§232.405~~Trading ~~of this chapter~~Symbol(s) ~~during~~Name ~~the~~of ~~preceding~~each 12exchange ~~months~~on ~~(or~~which ~~for~~registered ~~such~~None ~~shorter~~None ~~period that the registrant was required to submit such files). Yes ☒ No ☐~~None

Indicate by check mark whether the registrant is(1) ahas ~~large~~filed ~~accelerated~~all ~~filer,~~reports anrequired ~~accelerated~~to ~~filer,~~be afiled ~~non-accelerated~~by ~~filer,~~Section a13 ~~smaller~~or ~~reporting company,~~15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or anfor ~~emerging~~such ~~growth~~shorter ~~company.~~period ~~See~~that the ~~definitions~~registrant ofwas ~~“large~~required ~~accelerated~~to ~~filer,”~~file ~~“accelerated~~such ~~filer~~reports),~~” “smaller~~ ~~reporting~~and ~~company”~~(2) ~~and~~has ~~“emerging~~been ~~growth~~subject ~~company”~~to insuch ~~Rule~~filing ~~12b-2~~requirements offor the ~~Exchange~~past ~~Act~~90 days. x YES ¨ NO

~~Large~~Indicate ~~accelerated~~by ~~filer~~check ☐mark ~~Accelerated~~whether ~~filer~~the ☐registrant ~~Non~~has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-~~accelerated~~T ~~filer~~(§232.405 ☐of ~~Smaller~~this ~~reporting~~chapter) ~~company~~during ☒the ~~Emerging~~preceding ~~growth~~12 ~~company~~months ☐(or for such shorter period that the registrant was required to submit such files). x YES ¨ NO

~~If an~~Indicate ~~emerging growth company, indicate~~ by check mark ifwhether the registrant ~~has~~is ~~elected~~a ~~not~~large toaccelerated ~~use~~filer, ~~the~~an ~~extended~~accelerated ~~transition~~filer, ~~period~~a ~~for complying~~non-accelerated ~~with~~filer, ~~any~~a ~~new~~smaller reporting company, or ~~revised~~an ~~financial~~emerging ~~accounting~~growth ~~standards~~company. ~~provided~~See ~~pursuant~~the todefinitions ~~Section~~of ~~13(a)~~“large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. ☐

~~Indicate by~~Large ~~check~~accelerated ~~mark~~filer ~~whether~~¨ ~~the~~Accelerated ~~registrant~~filer is¨ aNon-accelerated ~~shell~~filer ~~company~~x ~~(as~~Smaller ~~defined~~reporting incompany ~~Rule~~x ~~12b-2~~Emerging ofgrowth ~~the~~company ~~Exchange Act). Yes ☒ No ☐~~¨

~~As of~~If ~~April~~an ~~29,~~emerging ~~2019~~growth company, ~~there~~indicate ~~were~~by ~~49,170,472~~check ~~shares~~mark ofif the ~~Company’s~~registrant ~~common~~has ~~stock,~~elected ~~par~~not ~~value~~to ~~$0.0001~~use ~~per~~the ~~share,~~extended ~~issued~~transition ~~and~~period ~~outstanding~~for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) x YES ¨ NO

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PRECEDING FIVE YEARS

Check whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Exchange Act after the distribution of securities under a plan confirmed by a court. ¨ YES ¨ NO

APPLICABLE ONLY TO CORPORATE ISSUERS

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

As of July 8, 2019, there were 49,170,472 shares of common stock, par value $0.0001 per share, issued and outstanding.

TABLE OF CONTENTS

		Page
PART I - FINANCIAL INFORMATION		F-1
PART I – FINANCIAL INFORMATION:
Item 1.	Financial Statements		F-1
Item 1.	Financial Statements:	F-1
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		4
	Balance Sheets as of February 28, 2019 and August 31, 2018 (Unaudited)	F-2
Item 3.	Quantitative and Qualitative Disclosures About Market Risk		8
	Statements of Operations for the Three and Six Months Ended February 28, 2019 and 2018 (Unaudited)	F-3
Item 4.	Controls and Procedures		8
	Statements of Stockholders’ Deficit for the Three and Six Months Ended February 28, 2019 and 2018 (Unaudited)	F-4
PART II - OTHER INFORMATION			9
	Statements of Cash Flows for the Six Months Ended February 28, 2019 and 2018 (Unaudited)	F-6
Item 1.	Legal Proceedings		9
	Notes to Unaudited Financial Statements	F-7
Item 1A.	Risk Factors		9
Item 2.	~~Management’s~~Unregistered ~~Discussion~~Sales ~~and Analysis~~ of ~~Financial~~Equity ~~Condition~~Securities and ~~Results~~Use of ~~Operations~~Proceeds	3	9
Item 3.	~~Quantitative~~Defaults ~~and~~Upon ~~Qualitative~~Senior ~~Disclosures About Market Risk~~Securities	6	9
Item 4.	~~Controls~~Mine ~~and~~Safety ~~Procedures~~Disclosures	6	9
PART II – OTHER INFORMATION:
Item 5.	Other Information		9
Item 1.	Legal Proceedings	7
Item 6.	Exhibits		9
Item 1A.	Risk Factors	7
SIGNATURES			10
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	7
Item 3.	Defaults Upon Senior Securities	7
Item 4.	Mine Safety Disclosures	7
Item 5.	Other Information	7
Item 6.	Exhibits	8

2 Table of Contents

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

ENTEST GROUP, INC.

INDEX TO UNAUDITED INTERIM FINANCIAL STATEMENTS

FOR THE PERIOD ENDED ~~FEBRUARY~~MAY 2831, 2019

		Page
Unaudited Balance Sheets		F-2
Unaudited Statements of Operations		F-3
Unaudited Statements of Stockholders’ Deficit		F-4
Unaudited Statements of Cash Flows		F-6
Notes to the Unaudited Financial Statements		F-7

F-1

ENTEST GROUP, INC.

Balance Sheets

(Unaudited)

	February 28,			August 31,
	May 31,			August 31,
	2019			2018
Assets
Current Assets
Cash	$	-		$	267
Accrued Interest Receivable		1,040			1,040
Prepaid expenses		-			8,000
Total Current Assets		1,040			9,307
Total Assets	$	1,040		$	9,307
Liabilities And Stockholders’ Deficit
Liabilities And Stockholders' Deficit
Current Liabilities
Accounts payable and accrued expenses	$	1013,~~740~~305		$	218,417
Unearned rental income		-			17,000
Due to related party		513,~~550~~627			-
Note payable		-			19,601
Total Current Liabilities		1626,~~290~~932			255,018
Total Liabilities		1626,~~290~~932			255,018
Stockholders’ Deficit
Stockholders' Deficit
Series AA Preferred stock: 100,000 shares authorized; $0.0001 par value
667 shares issued and outstanding		-			-
Series AAA Preferred stock: 300,000 shares authorized; $0.0001 par value
534 shares issued and outstanding		-			-
Series B Preferred stock: 4,400,000 shares authorized; $0.0001 par value
728,009 shares issued and outstanding		73			73
Non-Voting Convertible Preferred stock: 3,000,000 shares authorized; $1.00 par value;
1,001,533 shares issued and outstanding		1,001,533			1,001,533
Common stock- 500,000,000 shares authorized; $0.0001 par value
49,170,472 shares issued and outstanding		4,917			4,917
Additional paid in capital		9,025,314			9,003,892
Accumulated deficit		(10,~~047~~057,~~087~~729	)		(10,256,126	)
Total Stockholders’ Deficit		(15,250	)		(245,711	)
Total Stockholders' Deficit		(25,892	)		(245,711	)
Total liabilities and Stockholder’s Deficit	$	1,040		$	9,307
Total liabilities and Stockholder's Deficit	$	1,040		$	9,307

The accompanying Notes are an integral part of these unaudited interim financial statements.

F-2 Table of Contents

ENTEST GROUP, INC.

Statements of Operations

(Unaudited)

	For the						For the
	Three Months Ended						~~Six~~Nine Months Ended
	February 28,						February 28,
	May 31,						May 31,
	2019			2018			2019			2018
Revenue	$	-		$	-		$	-		$	-
Operating Expenses:
Research and development		-			~~290~~459,~~000~~584			-			~~290~~749,~~000~~584
Professional fees		68,~~395~~205			8480,~~091~~980			817,~~834~~039			~~208~~289,~~190~~170
General and administration		42,~~577~~437			5093,~~519~~075			1618,~~192~~629			~~99,~~192,267
Total operating expenses		10,~~972~~642			~~424~~633,~~610~~639			2535,~~026~~668			~~597~~1,~~382~~231,021
Operating Loss		(10,~~972~~642	)		(~~424~~633,~~610~~639	)		(2535,~~026~~668	)		(~~597~~1,~~382~~231,021	)
Other Income (Expense):
Rental income		-			15,000			28,000			3045,000
Gain on write of accounts payable		-			-			23,629			-
Gain on write off of accounts payable		-			-			23,629			-
Gain on disposition of Zander		-			-			188,589			-
Refund on amount previously paid		-			-			1,289			-
Interest Income		-			-			-			132
Loss on disposition Entest Biomedical		-			-			(6,947	)		-
Interest expense		-			(~~198~~361	)		(495	)		(~~532~~1,025	)
Total Other Income (Expense)		-			14,~~802~~639			234,065			2944,~~468~~107
Net Income (Loss) Before Income Tax		(10,~~972~~642	)		(~~409~~619,~~808~~000	)		~~209~~198,~~039~~397			(~~567~~1,186,914	)
Income tax provision		-			-			-			-
Net Income (Loss)	$	(10,~~972~~642	)	$	(~~409~~619,~~808~~000	)	$	~~209~~198,~~039~~397		$	(~~567~~1,186,914	)
Basic inceom (loss) per common share	$	(0.00	)	$	(0.01	)	$	0.00		$	(0.01	)
Basic income (loss) per common share	$	(0.00	)	$	(0.01	)	$	0.00		$	(0.02	)
Diluted income (loss) per common share	$	(0.00	)	$	(0.01	)	$	0.00		$	(0.0102	)
Weighted average number of common shares outstanding
Basic		49,170,472			49,170,472			49,170,472			49,~~073~~106,~~250~~134
Diluted		49,170,472			49,170,472			~~253~~153,~~564~~605,~~962~~613			49,~~073~~106,~~250~~134

The accompanying Notes are an integral part of these unaudited interim financial statements.

F-3 Table of Contents

~~ENTEST GROUP,~~Statements ~~INC.~~of Stockholders’ Deficit

~~Statements of~~For ~~Stockholders’~~the ~~Deficit~~Nine Months Ended May 31, 2019

~~For the Three and Six Months Ended February 28, 2019~~ (Unaudited)

(Unaudited)

													Non-Voting
													Convertible
	Series AA Preferred				Series AAA Preferred				Series B Preferred				Preferred Convertible Preferred				Common Stock				Additional Paid In		Accumulated
	Shares		Amount		Shares		Amount		Shares		Amount		Shares		Amount		Shares		Amount		Capital		Deficit			Total
Balance August 31, 2018		667	$	-		534	$	-		728,009	$	73		1,001,533	$	1,001,533		49,170,472	$	4,917	$	9,003,892	$	(10,256,126	)	$	(245,711	)

Contributed Capital		-		-		-		-		-		-		-		-		-		-		21,422		-			21,422
Net income for the period		-		-		-		-		-		-		-		-		-		-		-		220,011			220,011
Balance November 30, 2018		667	$	-		534	$	-		728,009	$	73		1,001,533	$	1,001,533		49,170,472	$	4,917	$	9,025,314	$	(10,036,115	)	$	(4,278	)

Net loss for the period		-		-		-		-		-		-		-		-		-		-		-		(10,972	)		(10,972	)
Balance February 28, 2019		667	$	-		534	$	-		728,009	$	73		1,001,533	$	1,001,533		49,170,472	$	4,917	$	9,025,314	$	(10,047,087	)	$	(15,250	)

Net loss for the period		-		-		-		-		-		-		-		-		-		-		-		(10,642	)		(10,642	)
Balance May 31, 2019		667	$	-		534	$	-		728,009	$	73		1,001,533	$	1,001,533		49,170,472	$	4,917	$	9,025,314	$	(10,057,729	)	$	(25,892	)

	Series AA Preferred				Series AAA Preferred				Series B Preferred				Non-Voting Convertible Preferred				Common Stock				Additional Paid-In		Accumulated
	Shares		Amount		Shares		Amount		Shares		Amount		Shares		Amount		Shares		Amount		Capital		Deficit			Total
Balance August 31, 2018		667	$	-		534	$	-		728,009	$	73		1,001,533	$	1,001,533		49,170,472	$	4,917	$	9,003,892	$	(10,256,126	)	$	(245,711	)
Contributed Capital		-		-		-		-		-		-		-		-		-		-		21,422		-			21,422
Net income for the period		-		-		-		-		-		-		-		-		-		-		-		220,011			220,011
Balance November 30, 2018		667		-		534		-		728,009		73		1,001,533		1,001,533		49,170,472		4,917		9,025,314		(10,036,115	)		(4,278	)
Contributed Capital
Net loss for the period		-		-		-		-		-		-		-		-		-		-		-		(10,972	)		(10,972	)
Balance February 28, 2019		667	$	-		534	$	-		728,009	$	73		1,001,533	$	1,001,533		49,170,472	$	4,917	$	9,025,314	$	(10,047,087	)	$	(15,250	)

The accompanying Notes are an integral part of these unaudited interim financial statements.

~~The accompanying~~F-4 ~~Notes~~Table ~~are an integral part~~ of ~~these unaudited interim financial statements.~~Contents

~~F-4~~ENTEST GROUP, INC.

~~ENTEST GROUP,~~Statements ~~INC.~~of Stockholders’ Deficit

~~Statements of~~For ~~Stockholders’~~the ~~Deficit~~ Nine Months Ended May 31, 2018

~~For the Three and Six Months Ended February 28, 2018~~(Unaudited)

(Unaudited)

													Non-Voting Convertible																Accumulated			Non-
	Series AA Preferred				Series AAA Preferred				Series B Preferred				Preferred Convertible Preferred						Common Stock				Additional Paid In			Accumulated			Other Comprehensive			Controlling Interest In
	Shares		Amount		Shares		Amount		Shares		Amount		Shares			Amount			Shares		Amount		Capital			Deficit			Income (Loss)			Subsidiary			Total
Balance August 31, 2017		667	$	-		534	$	-		728,009	$	73		1,026,533		$	1,026,533			46,670,472	$	4,667	$	7,465,656		$	(8,721,496	)	$	185,050		$	56,343		$	16,826

Common Shares issued for converison of Non-Voting Convertible Preferred Shares		-		-		-		-		-		-		(25,000	)		(25,000	)		2,500,000		250		24,750			-			-			-			-
Common Shares of subsidiary issued for cash		-		-		-		-		-		-		-			-			-		-		900,000			-			-			-			900,000
Accumulated Other Comprehensive Income		-		-		-		-		-		-		-			-			-		-		-			-			43,750			-			43,750
Non Controlling Interest in Subsidiary		-		-		-		-		-		-		-			-			-		-		(228,345	)		-			-			228,345			-
Net loss for the period		-		-		-		-		-		-		-			-			-		-		-			(158,106	)		-			-			(158,106	)
Balance November 30, 2017		667	$	-		534	$	-		728,009	$	73		1,001,533		$	1,001,533			49,170,472	$	4,917	$	8,162,061		$	(8,879,602	)	$	228,800		$	284,688		$	802,470

Common Shares of subsidiary issued for cash		-		-		-		-		-		-		-			-			-		-		200,000			-			-			-			200,000
Common Shares of subsidiary issued for cash		-		-		-		-		-		-		-			-			-		-		300,000			-			-			-			300,000
Accumulated other comprehensive loss		-		-		-		-		-		-		-			-			-		-		-			-			(90,300	)		-			(90,300	)
Non Controlling Interest in Subsidiary		-		-		-		-		-		-		-			-			-		-		(71,210	)		-			-			71,210			-
Net loss for the period		-		-		-		-		-		-		-			-			-		-		-			(409,809	)		-			-			(409,809	)
Balance February 28, 2018		667	$	-		534	$	-		728,009	$	73		1,001,533		$	1,001,533			49,170,472	$	4,917	$	8,590,851		$	(9,289,411	)	$	138,500		$	355,898		$	802,361

Accumulated other comprehensive loss		-		-		-		-		-		-		-			-			-		-					-			(65,800	)		-			(65,800	)
Non Controlling Interest in Subsidiary		-		-		-		-		-		-		-			-			-		-		246,219						-			(246,219	)		-
Declaration of property Dividend May 5, 2018		-		-		-		-		-		-		-			-			-		-		-			(57,143	)		-			-			(57,143	)
Net loss for the period		-		-		-		-		-		-		-			-			-		-					(619,000	)		-						(619,000	)
Balance May 31, 2018		667	$	-		534	$	-		728,009	$	73		1,001,533		$	1,001,533			49,170,472	$	4,917	$	8,837,070		$	(9,965,554	)	$	72,700		$	109,679		$	60,418

	Series AA Preferred				Series AAA Preferred				Series B Preferred				Non-Voting Convertible Preferred						Common Stock				Additional Paid-In		Accumulated			Accumulated Other Comprehensive			Non-Controlling Interest In
	Shares		Amount		Shares		Amount		Shares		Amount		Shares			Amount			Shares		Amount		Capital		Deficit			Income (Loss)			Subsidiary		Total
Balance August 31, 2017		667	$	—		534	$	—		728,009	$	73		1,026,533		$	1,026,533			46,670,472	$	4,667	$	7,465,656	$	(8,721,496	)	$	185,050		$	56,343	$	16,826
Common Shares issued for conversion of Non-Voting Convertible Preferred Shares		-		-		-		-		-		-		(25,000	)		(25,000	)		2,500,000		250		24,750		-			-			-		-
Common Shares of subsidiary issued for cash		-		-		-		-		-		-		-			-			-		-		900,000		-			-			-		900,000
Accumulated Other Comprehensive Income																													43,750					43,750
Net loss for the period																										(158,106	)							(158,106	)
Balance November 30, 2017		667		-		534		-		728,009		73		1,001,533			1,001,533			49,170,472		4,917		8,390,406		(8,879,602	)		228,800			56,343		802,470
Common Shares of subsidiary issued for cash		-		-		-		-		-		-		-			-			-		-		200,000		-			-			-		200,000
Common Shares of subsidiary issued for cash		-		-		-		-		-		-		-			-			-		-		300,000		-			-			-		300,000
Accumulated other comprehensive income		-		-		-		-		-		-		-			-			-		-		-		-			(90,300	)		-		(90,300	)
Net loss for the period		-		-		-		-		-		-		-			-			-		-		-		(409,809	)		—			-		(409,809	)
Balance February 28, 2018		667	$	-		534	$	-		728,009	$	73		1,001,533		$	1,001,533			49,170,472	$	4,917	$	8,890,406	$	(9,289,411	)	$	138,500		$	56,343	$	802,361

The accompanying Notes are an integral part of these unaudited interim financial statements.

~~The accompanying~~F-5 ~~Notes~~Table ~~are an integral part~~ of ~~these unaudited interim financial statements.~~Contents

~~F-5~~ENTEST GROUP, INC.

~~ENTEST GROUP,~~Statements ~~INC.~~of Cash Flows

~~Statements of Cash Flows~~(Unaudited)

(Unaudited)

	For the
	Nine Months Ended
	May 31,
	2019			2018

Cash Flows From Operating Activities:
Net income (loss)	$	198,397		$	(1,186,914	)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Loss on disposition Entest Biomedical		6,947			-
Gain on write off of accounts payable		(23,629	)		-
Gain on disposition of Zander		(188,589	)		-
Expenses paid by a related party		13,627			-
Changes in operating assets and liabilities:
Accrued interest receivable					(132	)
Accrued rental income receivable		(12,000	)		-
Accounts payable and accrued expenses		1,018			218,849
Unearned rental income		(7,730	)		20,000
Prepaid expenses		8,000			(117,388	)
Net Cash Used In Operating Activities		(3,959	)		(1,065,585	)

CASH FLOWS FROM INVESTING ACTIVITIES:
Net cash received for divestiture of Entest Biomedical		1,937			-
Net Cash Provided by Investing Activities		1,937			-

Cash Flows From Financing Activities:
Contributed capital		1,821			-
Proceeds from common stock issued from subsidiary		-			1,400,000
Repayment of bank overdraft		(66	)		-
Proceed from notes payable		-			3,000
Net Cash Provided by Financing Activities		1,755			1,403,000

Net Change in Cash		(267	)		337,415
Cash at Beginning of Period		267			86,559
Cash at End of Period	$	-		$	423,974

Supplemental Cash Flow Information:
Cash paid for interest	$	-		$	-
Cash paid for taxes	$	-		$	-

Supplemental disclosure of non-cash financing activity
Debt Satisfied through Contributed Capital	$	19,601		$	-

	For the
	Six Months Ended
	February 28,
	2019			2018
Cash Flows From Operating Activities:
Net income (loss)	$	209,039		$	(567,914	)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Loss on disposition Entest Biomedical		6,947			-
Gain on write off of accounts payable		(23,629	)		-
Gain on disposition of Zander		(188,589	)		-
Expenses paid by a related party		5,550			-
Changes in operating assets and liabilities:
Accrued rental income receivable		(12,000	)		-
Accounts payable and accrued expenses		(1,547	)		(64,316	)
Unearned rental income		(7,730	)		5,000
Prepaid expenses		8,000			(117,388	)
Net Cash Used In Operating Activities		(3,959	)		(744,618	)
CASH FLOWS FROM INVESTING ACTIVITIES:
Net cash received for divestiture of Entest Biomedical		1,937			-
Net Cash Provided by Investing Activities		1,937			-
Cash Flows From Financing Activities:
Proceed additional paid in Capital		1,821			-
Proceeds from common stock issued from subsidiary		-			1,400,000
Bank overdraft		(66	)		-
Net Cash Provided by Financing Activities		1,755			1,400,000
Net Change in Cash		(267	)		655,382
Cash at Beginning of Period		267			86,559
Cash at End of Period	$	-		$	741,941
Supplemental Cash Flow Information:
Cash paid for interest	$	-		$	-
Cash paid for taxes	$	-		$	-
Supplemental disclosure of non-cash financing activity
Debt Satisfied through Contributed Capital	$	19,601		$	-

The accompanying Notes are an integral part of these unaudited interim financial statements.

~~The accompanying~~F-6 ~~Notes~~Table ~~are an integral part~~ of ~~these unaudited interim financial statements.~~Contents

~~F-6~~ENTEST GROUP, INC.

~~ENTEST GROUP,~~Notes ~~INC.~~ to the Unaudited Financial Statements

~~Notes to~~As ~~the~~of ~~Unaudited~~May ~~Financial~~31, ~~Statements~~ 2019

~~As of~~NOTE ~~February~~1. 28ORGANIZATION, ~~2019~~DESCRIPTION OF BUSINESS, AND GOING CONCERN

~~NOTE 1~~Entest Group, Inc. ~~ORGANIZATION~~(the “Company” or “Entest”) was incorporated in the State of Nevada on September 24, ~~DESCRIPTION~~2008 OFas ~~BUSINESS~~JB Clothing Corporation. On July 12, ~~AND~~2009, ~~GOING~~the ~~CONCERN~~Company changed its name to Entest BioMedical, Inc. On February 12, 2018 the Company changed its name from Entest BioMedical, Inc. to Entest Group, Inc.

~~Entest Group,~~The ~~Inc.~~Company’s ~~(the~~current ~~“Company”or~~business ~~“Entest”)~~strategy ~~was~~is ~~incorporated~~to inacquire ~~the~~an ~~State~~operating ofcompany ~~Nevada~~seeking onthe ~~September~~perceived ~~24,~~advantages ~~2008~~of ~~as JB~~being ~~Clothing~~a ~~Corporation~~publicly held corporation. OnNo ~~July~~assurance ~~12,~~can ~~2009,~~be ~~the~~given ~~Company~~that ~~changed~~such ~~its~~an ~~name~~acquisition toshall ~~Entest~~occur ~~BioMedical~~or, ~~Inc.~~if Onsuch ~~February~~an ~~12,~~acquisition ~~2018~~were ~~the~~to ~~Company changed~~occur, ~~its~~it ~~name~~would ~~from~~occur ~~Entest~~on ~~BioMedical,~~terms ~~Inc.~~and conditions beneficial to ~~Entest~~the ~~Group,~~Company ~~Inc~~or its shareholders.

~~The Company’s~~Change ~~current business strategy is to acquire an operating company seeking the perceived advantages~~ of being a publicly held corporation. No assurance can be given that such an acquisition shall occur or, if such an acquisition were to occur, it would occur on terms and conditions beneficial to the Company or its shareholders.Control

~~Change~~ On November 15, 2018, David Koos, Regen BioPharma Inc., Bostonia Partners Inc., Sherman Family Trust, Dunhill Ross Partners Inc., Bio-Technology Partners Business Trust (collectively, the “Sellers”) and Peiwen Yu (the “Buyer”) entered into a stock purchase agreement (the “SPA”), pursuant to which the Sellers agreed to sell and the Buyer agreed to purchase an aggregate of ~~Control~~23,733,334 shares of common stock, 667 shares of Series AA preferred stock, 534 shares of Series AAA preferred stock and 1,001,533 shares of Non-Voting Preferred Stock of Entest from the Seller for an aggregate purchase price of $325,000. The closing of the transactions contemplated by the SPA occurred on November 27, 2018. The purchase price was paid out of the Buyer’s personal funds.

~~On November~~As ~~15,~~of ~~2018,~~the ~~David~~date ~~Koos,~~of ~~Regen~~the ~~BioPharma Inc.~~transaction, ~~Bostonia~~Entest ~~Partners~~had ~~Inc.~~49, ~~Sherman Family Trust~~170,472 ~~Dunhill~~shares ~~Ross~~of ~~Partners~~common ~~Inc., Bio-Technology Partners Business Trust (collectively, the “Sellers”) and Peiwen Yu (the “Buyer”) entered into a~~ stock ~~purchase agreement (the “SPA”)~~, ~~pursuant to which the Sellers agreed to sell and the Buyer agreed to purchase an aggregate of 23~~728,~~733,334~~009 shares of ~~common~~Series ~~stock~~B Preferred Stock, 667 shares of Series AA ~~preferred~~Preferred ~~stock~~Stock, 534 shares of Series AAA ~~preferred~~ ~~stock~~Preferred Stock and 1,001,533 shares of Non-Voting Convertible Preferred Stock ofoutstanding. ~~Entest~~The ~~from~~securities purchased pursuant to the ~~Seller~~SPA ~~for~~represent an48.3% ~~aggregate~~of ~~purchase~~the ~~price~~outstanding shares of ~~$325,000.~~ ~~The~~common ~~closing~~stock, 90% of the ~~transactions~~outstanding ~~contemplated~~shares byof common stock assuming the ~~SPA~~conversion ~~occurred~~of the Non-Voting Convertible Preferred Stock on ~~November~~the ~~27,~~execution ~~2018.~~date ~~The~~of ~~purchase~~the ~~price~~SPA ~~was~~and ~~paid~~94% ~~out~~ of the ~~Buyer’s~~voting ~~personal~~power ~~funds~~of Entest.

As of ~~the~~contemplated ~~date~~by of the ~~transaction~~SPA, ~~Entest~~in ~~had~~November 492018,~~170,472~~ ~~shares~~David ofKoos ~~common~~resigned ~~stock,~~as ~~728~~Chairman,~~009~~ ~~shares~~Chief ofExecutive ~~Series~~Officer, ~~B Preferred Stock~~President, ~~667 shares~~Acting ofChief ~~Series~~Financial AAOfficer ~~Preferred~~and ~~Stock,~~Secretary ~~534~~of ~~shares~~Entest ofand ~~Series~~Peiwen ~~AAA~~Yu ~~Preferred~~became ~~Stock~~as ~~and~~a 1director,~~001,533~~ ~~shares~~Chief ofExecutive ~~Non-Voting~~Officer ~~Convertible~~and ~~Preferred Stock~~President ~~outstanding~~of Entest. ~~The~~Pursuant ~~securities purchased pursuant~~ to the SPA, ~~represent~~in ~~48.3%~~November of2018, ~~the~~Mr. ~~outstanding~~Koos ~~shares~~also ofresigned ~~common~~as ~~stock,~~a ~~90%~~ director of the ~~outstanding~~Company ~~shares~~upon ofcompliance ~~common~~by ~~stock~~Entest ~~assuming~~with ~~the~~information ~~conversion~~statement ofdelivery ~~the~~requirements ~~Non-Voting~~pursuant ~~Convertible~~to ~~Preferred~~Rule ~~Stock~~14f-1 onunder the ~~execution date~~Securities ofExchange ~~the~~Act ~~SPA~~of ~~and~~1934, ~~94%~~as ofamended (the ~~voting~~“Exchange ~~power of Entest~~Act”).

~~As contemplated~~Going byConcern ~~the SPA, in November 2018, David Koos resigned as Chairman, Chief Executive Officer, President, Acting Chief Financial Officer~~ and ~~Secretary~~Liquidity of Entest and Peiwen Yu became as a director, Chief Executive Officer and President of Entest. Pursuant to the SPA, in November 2018, Mr. Koos also resigned as a director of the Company upon compliance by Entest with information statement delivery requirements pursuant to Rule 14f-1 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).Considerations

~~Going Concern~~The accompanying unaudited interim financial statements have been prepared on a going concern basis, which contemplates the realization of assets and ~~Liquidity~~the ~~Considerations~~satisfaction of liabilities in the normal course of business. The Company has not generated any revenues since the change of control and disposition of its subsidiaries, and has an accumulated deficit of $10,057,729. These factors among others raise substantial doubt about the ability of the Company to continue as a going concern for a reasonable period of time. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.

The ~~accompanying~~ ~~unaudited~~continuing ~~interim~~operations ~~financial statements have been prepared on a going concern basis, which contemplates the realization~~ of ~~assets and~~ the ~~satisfaction of liabilities in the normal course of business. The~~ Company ~~has~~are ~~not~~dependent ~~generated~~upon ~~any revenues since the change of control and disposition of~~ its ~~subsidiaries, and has an accumulated deficit of $10,047,087. These factors among others raise substantial doubt about the~~ ability ~~of the Company~~ to continue asto araise ~~going~~adequate ~~concern~~financing ~~for~~and ato ~~reasonable~~commence ~~period~~profitable ofoperations ~~time. The~~in ~~accompanying~~the ~~financial~~future ~~statements~~and dorepay ~~not~~its ~~include~~liabilities ~~any~~arising ~~adjustments~~from ~~that~~normal ~~might~~business ~~result~~operations ~~from~~as ~~the~~they ~~outcome~~become ~~of this uncertainty~~due.

~~The continuing~~In ~~operations~~support of the Company’s ~~are~~efforts ~~dependent~~and ~~upon~~cash ~~its~~requirements, ~~ability~~it tomay ~~continue~~rely toon ~~raise~~advances ~~adequate~~from ~~financing~~related ~~and~~parties tountil ~~commence~~such ~~profitable operations~~time inthat the ~~future~~Company ~~and~~can ~~repay~~support its ~~liabilities~~operations ~~arising~~or ~~from~~attains ~~normal~~adequate ~~business~~financing ~~operations~~through assales ~~they~~of ~~become~~its ~~due~~equity or traditional debt financing. There is no formal written commitment for continued support by shareholders or directors.

~~In support~~F-7 ofTable ~~the Company’s efforts and cash requirements, it may rely on advances from related parties until such time that the Company can support its operations or attains adequate financing through sales~~ of ~~its equity or traditional debt financing. There is no formal written commitment for continued support by shareholders or directors.~~Contents

~~F-7~~NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

~~NOTE 2.~~Basis ~~SUMMARY~~of ~~OF SIGNIFICANT ACCOUNTING POLICIES~~Presentation

~~Basis~~ The accompanying unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of ~~Presentation~~America for interim financial statements and with the instructions to Form 10-Q and Article 8 of Regulation S-X of the United States Securities and Exchange Commission (“SEC”). Accordingly, they do not contain all information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. In the opinion of the Company’s management, the accompanying unaudited financial statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of May 31, 2019 and the results of operations, statements of changes in stockholders’ deficit and cash flows for the periods presented. The results of operations for the period ended May 31, 2019 are not necessarily indicative of the operating results for the full fiscal year or any future period. These unaudited interim financial statements should be read in conjunction with the financial statements and related notes thereto included in the Company’s Annual Report on Form 10-K for the year ended August 31, 2018 filed with the Securities and Exchange (the “SEC”) on November 28, 2018.

The accompanying unaudited interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial statements and with the instructions to Form 10-Q and Article 8 of Regulation S-X of the United States Securities and Exchange Commission (“SEC”). Accordingly, they do not contain all information and footnotes required by accounting principles generally accepted in the United States of America for annual financial statements. In the opinion of the Company’s management, the accompanying unaudited financial statements contain all the adjustments necessary (consisting only of normal recurring accruals) to present the financial position of the Company as of February 28, 2019 and the results of operations and cash flows for the periods presented. The results of operations for the period ended February 28, 2019 are not necessarily indicative of the operating results for the full fiscal year or any future period. These unaudited interim financial statements should be read in conjunction with the financial statements and related notes thereto included in the Company’s Annual Report on Form 10-K for the year ended August 31, 2018 filed with the Securities and Exchange (the “SEC”) on November 28, 2018.Reclassifications

~~Reclassifications~~Certain prior year amounts have been reclassified to conform with the current year presentation.

~~Certain prior~~Recent ~~year~~Accounting ~~amounts have been reclassified to conform with the current year presentation.~~Pronouncements

~~Recent Accounting~~In ~~Pronouncements~~October 2018, FASB issued ASU No. 2018-17, Consolidation - Targeted Improvements to Related Party Guidance for Variable Interest Entities (Topic 810). ASU No. 2018-17 guidance eliminates the requirement that entities consider indirect interests held through related parties under common control in their entirety when assessing whether a decision-making fee is a variable interest. Instead, the reporting entity will consider such indirect interests on a proportionate basis. This pronouncement is effective for public entities for fiscal years ending after December 15, 2019, with early adoption permitted. The Company does not expect the adoption to have a material impact on its consolidated financial statements.

~~In October~~NOTE ~~2018, FASB issued ASU No~~3. ~~2018-17,~~RELATED ~~Consolidation~~PARTY - Targeted Improvements to Related Party Guidance for Variable Interest Entities (Topic 810). ASU No. 2018-17 guidance eliminates the requirement that entities consider indirect interests held through related parties under common control in their entirety when assessing whether a decision-making fee is a variable interest. Instead, the reporting entity will consider such indirect interests on a proportionate basis. This pronouncement is effective for public entities for fiscal years ending after December 15, 2019, with early adoption permitted. The Company does not expect the adoption to have a material impact on its consolidated financial statements.TRANSACTIONS

~~NOTE~~ On July 3, 2018, Zander entered into a sublease agreement with Entest whereby Zander would sublet office space located at 4700 Spring Street, Suite 304, La Mesa, California 91942 from Entest on a month to month basis for $6,000 per month beginning July 5, 2018. ~~RELATED~~On ~~PARTY~~November ~~TRANSACTIONS~~16, 2018 Zander Therapeutics Inc. and the Company agreed to terminate Zander’s sublease with the Company effective the rental period commencing November, 2018. David R. Koos, who served as Chairman and Chief Executive Officer of Zander as of that date also served as Chairman and Chief Executive Officer of Entest as of that date. Zander was under common control with Entest as of that date.

On ~~July~~ 3November 16, 2018, ~~Zander~~Entest ~~entered~~Group, ~~into~~Inc. aand ~~sublease~~its ~~agreement~~then ~~with~~Chairman ~~Entest~~and ~~whereby~~Chief ~~Zander~~Executive ~~would~~Officer, ~~sublet~~David ~~office~~R. ~~space~~Koos, ~~located~~agreed atto ~~4700~~satisfy ~~Spring Street,~~any ~~Suite~~and ~~304,~~all Launpaid ~~Mesa,~~interest ~~California~~resulting ~~91942~~ from ~~Entest~~accrued interest earned on aNotes ~~month~~Payable to ~~month~~Koos ~~basis~~by ~~for~~Entest ~~$6,000~~from ~~per~~the ~~month~~ beginning ~~July~~of 5,time ~~2018. On~~to November 1630, 2018 ~~Zander~~by ~~Therapeutics~~transferring ~~Inc. and the Company agreed~~ to ~~terminate Zander’s sublease with the Company effective the rental period commencing November, 2018.~~ David R. Koos 3,000,000 ~~who~~shares ~~served~~of asthe ~~Chairman~~Series ~~and~~M ~~Chief~~Preferred ~~Executive~~stock ~~Officer~~ of Zander asTherapeutics, ~~of that date also served as Chairman and Chief Executive Officer of Entest as of that date~~Inc. ~~Zander~~owned ~~was~~by ~~under~~the ~~common control with Entest as of that date~~Company.

~~On November 16, 2018,~~ Entest Group, Inc. and ~~its~~Blackbriar ~~then~~Partners ~~Chairman~~(“BP”) ~~and Chief Executive Officer, David R. Koos,~~ agreed to satisfy any and all unpaid interest resulting from accrued interest earned on Notes Payable to ~~Koos~~BP by Entest from the ~~beginning~~Company’s ofinception ~~time~~ to November 30, 2018 by transferring to ~~David~~BP ~~R. Koos 3~~20,000~~,000~~ shares of the Series M Preferred stock of Zander Therapeutics, Inc. owned by the Company. BP is controlled by David Koos, as of that date, the Company’s then Chairman and Chief Executive Officer.

Entest Group, Inc. and ~~Blackbriar~~the ~~Partners~~Bio Matrix Scientific Group, Inc. (“BPBMSN”) agreed to satisfy any and all unpaid interest resulting from accrued interest earned on Notes Payable to BPBMSN by Entest from the Company’s inception to November 30, 2018 by transferring to BPBMSN 205,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. owned by the Company. BPAs isof ~~controlled~~November by16, ~~David Koos~~2018, asDavid ofR. ~~that date,~~Koos was the ~~Company’s then~~ Chairman and Chief Executive Officer of the Company and BMSN.

~~Entest Group,~~F-8 ~~Inc.~~Table and the Bio Matrix Scientific Group, Inc. (“BMSN”) agreed to satisfy any and all unpaid interest resulting from accrued interest earned on Notes Payable to BMSN by Entest from the Company’s inception to November 30, 2018 by transferring to BMSN 5,000 shares of ~~the Series M Preferred stock of Zander Therapeutics, Inc. owned by the Company. As of November 16, 2018, David R. Koos was the Chairman and Chief Executive Officer of the Company and BMSN.~~Contents

~~F-8~~Entest Group, Inc. and Regen Biopharma, Inc. (“RGBP”) agreed to satisfy any and all unpaid interest resulting from accrued interest earned on Notes Payable to RGBP by Entest from the beginning of time to November 30, 2018 by transferring to RGBP 250,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. owned by the Company.

Entest Group, Inc. and Regen Biopharma, Inc. (“RGBP”) agreed to satisfy any and all ~~unpaid~~rent ~~interest~~prepaid ~~resulting~~by ~~from~~RGBP ~~accrued interest earned on Notes Payable~~ to ~~RGBP by~~ Entest from the beginning of time to November 30, 2018 by transferring to RGBP ~~250~~475,000 shares of the Series M Preferred stock of Zander Therapeutics, Inc. owned by the Company. As of November 16, 2018, David R. Koos was the Chairman and Chief Executive Officer of the Company and RGBP.

~~Entest Group,~~In ~~Inc.~~November ~~and Regen Biopharma~~2018, ~~Inc.~~the ~~(“RGBP”)~~Company ~~agreed~~divested toitself ~~satisfy~~of ~~any and all rent prepaid by RGBP to~~ Entest ~~from~~BioMedical, ~~the beginning of time to November 30~~Inc., ~~2018~~a byCalifornia ~~transferring to RGBP 475~~corporation,~~000~~ ~~shares~~for ofconsideration ~~the~~consisting ~~Series M Preferred stock~~ of ~~Zander Therapeutics~~$2, ~~Inc.~~000 ~~owned~~paid by ~~the~~an ~~Company.~~entity Ascontrolled ofby ~~November 16, 2018,~~ David R. Koos ~~was the Chairman and Chief Executive Officer of the Company and RGBP~~.

~~In November~~The ~~2018, the~~ Company ~~divested~~recognized ~~itself~~a loss of ~~Entest BioMedical~~$6,947 ~~Inc.,~~on athe ~~California~~disposition ~~corporation,~~based ~~for~~on ~~consideration~~the ~~consisting of~~difference ~~$2,000~~between ~~paid~~the byNet anAssets ~~entity~~of ~~controlled~~the bysubsidiary ~~David~~and R.the ~~Koos~~consideration paid.

~~The~~ During the period ended May 31, 2019, the Company’s ~~recognized~~sole aofficer ~~loss~~advanced to the Company an amount of $613,~~947~~627 onby ~~the~~issuing ~~disposition~~an ~~based~~unsecured onand ~~the~~non-interest ~~difference~~bearing ~~between~~loan ~~the~~that ~~Net~~is ~~Assets~~payable on demand. As of ~~the~~May ~~subsidiary~~31, 2019 and August 31, 2018, the ~~consideration~~ ~~paid~~balance of such loan was $13,627 and $0, respectively.

~~During the~~NOTE ~~period~~4. ~~ended February 29, 2019, the Company~~STOCKHOLDERS’s sole officer advanced to the Company an amount of $5,550 by issuing an unsecured and non-interest bearing loan that is payable on demand. As of February 29, 2019 and August 31, 2018, the balance of such loan was $5,550 and $0, respectively.EQUITY

~~NOTE 4.~~Authorized ~~STOCKHOLDERS’ EQUITY~~Stock

~~Authorized Stock~~The Company is authorized to issue an aggregate of 500,000,000 shares of common stock with a par value of $0.0001, 5,000,000 shares of preferred stock with a par value of $0.0001, and 3,000,000 shares of non-voting convertible preferred stock with a par value of $1.00. Each share of common stock entitles the holder to one vote on any matter on which action of the stockholders of the corporation is sought.

~~The Company~~Series isAA ~~authorized~~Preferred to issue an aggregate of 500,000,000 shares of common stock with a par value of $0.0001, 5,000,000 shares of preferred stock with a par value of $0.0001, and 3,000,000 shares of non-voting convertible preferred stock with a par value of $1.00. Each share of common stock entitles the holder to one vote on any matter on which action of the stockholders of the corporation is sought.Stock

The Company is authorized to issue 100,000 shares of Series AA Preferred Stock at a par value of $0.0001 per share.

~~The Company~~As isof ~~authorized~~May to31, ~~issue~~2019 ~~100~~and August 31,~~000~~ 2018, 667 shares of Series AA Preferred Stock atwere aissued ~~par~~and ~~value of $0~~outstanding.~~0001 per share.~~

~~As of February 28, 2019 and August 31, 2018, 667 shares of~~ Series AAB Preferred Stock ~~were issued and outstanding.~~

The Company is authorized to issue 4,400,000 shares of Series B Preferred Stock at a par value of $0.0001 per share.

~~The Company~~As isof ~~authorized~~May to31, ~~issue~~2019 4and August 31,~~400~~ 2018,~~000~~ 728,009 shares of Series B Preferred Stock atwere aissued ~~par~~and ~~value of $0~~outstanding.~~0001 per share.~~

~~As of February 28, 2019 and August 31, 2018, 728,009 shares of~~ Series BAAA Preferred Stock ~~were issued and outstanding.~~

The Company is authorized to issue 300,000 shares of Series AAA Preferred Stock at a par value of $0.0001 per share.

~~The Company~~As isof ~~authorized~~May to31, ~~issue~~2019 ~~300~~and August 31,~~000~~ 2018, 534 shares of Series AAA Preferred Stock atwere aissued ~~par~~and ~~value of $0~~outstanding.~~0001 per share.~~

~~As of~~Non-Voting ~~February~~Convertible ~~28, 2019 and August 31, 2018, 534 shares of Series AAA~~ Preferred Stock ~~were issued and outstanding.~~

FThe Company is authorized to issue 3,000,000 shares of Non-9Voting Convertible Preferred Stock at a par value of $1.00 per share.

On October 2, 2018, the Company amended Article 4 of its Articles of Incorporation to change the conversion features of the Company’s Non -Voting Convertible Preferred Stock. The Conversion Price changed from being equal to the greater of $0.01 per share or seventy percent (70%) of the lowest closing bid price of its shares of common stock (the “Closing Price”) on its principal trading market or exchange for the five (5) trading days immediately preceding written receipt by the corporation of the holder’s intent to convert to being equal to the greater of (i) $0.001 per share and (ii) seventy percent (70%) of the lowest Closing Price for the five (5) trading days immediately preceding written receipt by the corporation of the holder’s intent to convert.

~~The Company is authorized to issue 3,000,000 shares of Non~~F-~~Voting~~9 ~~Convertible~~Table ~~Preferred Stock at a par value~~ of ~~$1.00 per share.~~Contents

~~On October~~As ~~2, 2018, the Company amended Article 4~~ of ~~its~~May ~~Articles~~31, of2019 ~~Incorporation~~and toAugust ~~change~~31, ~~the~~2018, ~~conversion~~1,001,533 ~~features~~shares of ~~the Company’s~~ Non -Voting Convertible Preferred Stock. ~~The~~were ~~Conversion~~issued Price changed from being equal to the greater of $0.01 per share or seventy percent (70%) of the lowest closing bid price of its shares of common stock (the “Closing Price”) on its principal trading market or exchange for the five (5) trading days immediately preceding written receipt by the corporation of the holder’s intent to convert to being equal to the greater of (i) $0.001 per share and ~~(ii) seventy percent (70%) of the lowest Closing Price for the five (5) trading days immediately preceding written receipt by the corporation of the holder’s intent to convert~~outstanding.

~~As of~~Common ~~February 28, 2019 and August 31, 2018, 1,001,533 shares of Non-Voting Convertible Preferred Stock were issued and outstanding.~~Shares

The Company is authorized to issue 500,000,000 shares of Common ~~Shares~~ Stock at a par value of $0.0001 per share.

~~The Company~~As isof ~~authorized~~May to31, ~~issue~~2019 ~~500~~and August 31,~~000~~ 2018,~~000~~ 49,170,472 shares of Common Stock atwere aissued ~~par~~and ~~value of $0~~outstanding.~~0001 per share.~~

~~As of~~NOTE ~~February~~4. ~~28,~~DECONSOLIDATION ~~2019~~OF ~~and~~ZANDER ~~August 31~~THERAPEUTICS, ~~2018, 49,170,472 shares of Common Stock were issued and outstanding~~INC.

~~NOTE 4~~On May 5, 2018, The Company declared the distribution on a pro rata basis as a dividend in kind of 3,000,000 of the common shares of Zander Therapeutics, Inc., ~~DECONSOLIDATION~~par OFvalue ~~ZANDER~~$0.0001, ~~THERAPEUTICS~~currently owned by Entest Group, ~~INC~~Inc. to:

~~On May~~(a) 5,Holders ~~2018,~~of ~~The~~record ~~Company~~of ~~declared~~ the ~~distribution~~outstanding oncommon ashares ~~pro~~of ~~rata~~the ~~basis~~Company as ~~a dividend in kind~~ of ~~3,000,000 of~~ the ~~common~~record ~~shares of Zander Therapeutics~~date, ~~Inc.,~~which ~~par~~is ~~value~~May ~~$0.0001~~30, ~~currently owned by Entest Group, Inc~~2018. ~~to:~~

(ab) Holders of record of the shares of any outstanding ~~common~~series of the preferred shares of the Company as of the record date, which is May 30, 2018.

~~(b) Holders~~Shareholders of ~~record~~the Company shall receive one (1) share of ~~the~~common ~~shares~~stock of ~~any~~Zander ~~outstanding~~Therapeutics, ~~series~~Inc. offor ~~the~~each ~~preferred~~17 shares of the Company’s common and/or preferred stock held as of the record date for such dividend. The distribution of the 3,000,000 ~~which is~~common ~~May~~shares 30of Zander Therapeutics, Inc. to the common and preferred shareholders of the Company occurred on June 11, 2018 (“Distribution Date”).

~~Shareholders~~ As a result of the ~~Company~~payment ~~shall~~of ~~receive~~the ~~one~~abovementioned ~~(1)~~property ~~share~~dividend, ofthe ~~common~~Company’s ~~stock~~percentage of ownership of Zander ~~Therapeutics,~~fell ~~Inc.~~below ~~for~~50% ~~each~~resulting 17in ~~shares~~the deconsolidation of ~~the~~Zander ~~Company’s common~~as ~~and/or~~of ~~preferred~~the ~~stock~~Distribution ~~held~~Date. asAs of the ~~record~~Distribution ~~date~~Date ~~for~~all ~~such~~assets ~~dividend~~and liabilities attributable to Zander were derecognized by the Company. The ~~distribution~~Company ofrecognized ~~the~~a 3$10,~~000,000~~034 ~~common~~gain ~~shares~~as a result of ~~Zander~~ ~~Therapeutics,~~the ~~Inc~~deconsolidation. The Property dividend may be deemed to ~~the~~have ~~common~~occurred ~~and~~with ~~preferred~~a related party as the recipients were shareholders of Entest, including the ~~Company~~then ~~occurred~~Chairman onand ~~June~~Chief 11Executive Officer of Entest and Regen Biopharma, ~~2018~~Inc. ~~(“Distribution Date”)~~which was a company under common control with Entest.

~~As a~~The ~~result~~Company’s ofremaining ~~the~~shares ~~payment~~ of ~~the~~Zander, ~~abovementioned~~which ~~property~~consisted ~~dividend~~of 5,000,000 ~~the~~shares ~~Company~~of Zander’s ~~percentage~~Series ofM ~~ownership~~Preferred ofStock (“Zander ~~fell~~M ~~below 50%~~Stock”) ~~resulting~~were inaccounted ~~the~~for ~~deconsolidation~~under ofthe ~~Zander~~Equity Method as of the Distribution Date until November 29, 2018. AsThe ofZander ~~the~~M ~~Distribution~~Stock ~~Date~~was ~~all~~carried ~~assets~~a Fair Value and ~~liabilities attributable~~the tocarrying ~~Zander~~value ~~were~~was ~~derecognized~~increased by the Company.’s ~~The~~proportionate ~~Company~~share ~~recognized~~of aearnings ~~$10,034~~of ~~gain~~Zander and decreased by cash dividends paid by Zander as awell ~~result~~as the Company’s proportionate share of losses of Zander up to the ~~deconsolidation~~carrying value. ~~The~~ ~~Property~~As ~~dividend~~of ~~may~~August be31, ~~deemed~~2018, tothe ~~have~~carrying ~~occurred~~value ~~with~~of athe ~~related~~Zander ~~party~~M asStock was decreased by the ~~recipients~~Company’s ~~were~~proportionate ~~shareholders~~share of ~~Entest, including~~ the ~~then~~losses ~~Chairman~~of Zander and ~~Chief~~was ~~Executive~~0. ~~Officer~~As of ~~Entest~~August ~~and~~31, ~~Regen Biopharma~~2018, ~~Inc.~~Entest ~~which~~beneficially ~~was~~owned a34.82% ~~company~~of ~~under~~the ~~common~~share ~~control~~equity ~~with Entest~~of Zander.

~~The Company’s~~During ~~remaining~~the ~~shares~~quarter ofended ~~Zander~~November 30, ~~which consisted of 5~~2018,~~000,000~~ ~~shares of Zander’s Series M Preferred Stock (“Zander M Stock”) were accounted for under~~ the ~~Equity~~Company ~~Method~~divested asitself of the ~~Distribution Date until November 29, 2018. The~~ Zander M Stock ~~was~~ ~~carried~~as asatisfaction ~~Fair Value and the carrying value was increased by the Company’s proportionate share~~ of ~~earnings~~$179,318 of ~~Zander and~~interest ~~decreased~~accrued bybut ~~cash~~unpaid ~~dividends~~owed ~~paid~~ by ~~Zander as well as~~ the Company’s ~~proportionate~~and ~~share~~$9,270 of ~~losses~~unearned ofrental ~~Zander~~payments upmade to the ~~carrying~~ ~~value~~Company. As ~~of August 31, 2018,~~ the ~~carrying value of the~~ Zander M Stock ~~was~~had ~~decreased~~a bycarrying ~~the~~value ~~Company’s proportionate share~~ of $0, the ~~losses~~Company ofrecognized ~~Zander~~a ~~and~~gain ~~was 0. As~~ of ~~August 31~~$188,589 ~~2018,~~on ~~Entest beneficially owned 34.82% of~~ the ~~share equity of Zander~~disposition.

~~During the~~NOTE ~~quarter~~5. ~~ended~~DISPOSITION ~~November~~OF ~~30,~~ENTEST ~~2018~~BIOMEDICAL, ~~the Company divested itself of the Zander M Stock as satisfaction of $179,318 of interest accrued but unpaid owed by the Company and $9,270 of unearned rental payments made to the Company~~INC. ~~As the Zander M Stock had a carrying value of $0~~, ~~the~~A ~~Company~~CALIFORNIA ~~recognized a gain of $188,589 on the disposition.~~CORPORATION

~~F-10~~During the quarter ended November 30, 2018 the Company divested itself of Entest Biomedical, Inc., a California corporation and wholly owned subsidiary, for consideration consisting of $2,000 paid by an entity controlled by the Company’s then Chairman and Chief Executive Officer, David R. Koos, as full consideration for Entest Biomedical Inc. as well as any and all furniture, fixtures and equipment owned by the Company which has a carrying amount of $0.

~~NOTE 5.~~F-10 ~~DISPOSITION~~Table OFof ~~ENTEST BIOMEDICAL, INC., A CALIFORNIA CORPORATION~~Contents

~~During the~~The ~~quarter ended November 30, 2018 the~~ Company ~~divested~~recognized ~~itself of Entest Biomedical, Inc.,~~ a ~~California~~loss ~~corporation and wholly owned subsidiary, for consideration consisting~~ of $26,~~000~~947 ~~paid~~on bythe andisposition ~~entity~~based ~~controlled~~on by the ~~Company’s~~difference ~~then~~between ~~Chairman~~the ~~and Chief~~Net ~~Executive~~Assets ~~Officer,~~of ~~David~~the R.subsidiary ~~Koos, as full consideration for Entest Biomedical Inc. as well as any~~ and ~~all furniture, fixtures and equipment owned by~~ the ~~Company~~Consideration ~~which has a carrying amount of $0~~paid.

The Company recognized a loss of $6,947 on the disposition based on the difference between the Net Assets of the subsidiary and the Consideration paid.

Cash derecognized in Divestiture	$	(63	)
Accrued Rent Receivable Derecognized in Divestiture	$	(12,000	)
Liabilities Derecognized in Divestiture	$	3,116

Consideration Received in Divestiture	$	2,000
Loss Recognized in Divestiture	$	(6,947	)

Cash derecognized in Divestiture	(63	)
Accrued Rent Receivable Derecognized in Divestiture	(12,000	)
Liabilities Derecognized in Divestiture	3,116
Consideration Received in Divestiture	2,000
Loss Recognized in Divestiture	(6,947	)

NOTE 6. INCOME TAXES

~~NOTE~~The 6Company provides for income taxes under ASC 740, “Income Taxes. ~~INCOME~~” ~~TAXES~~Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax basis of assets and liabilities and the tax rates in effect when these differences are expected to reverse. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations.

The ~~Company provides for~~ income ~~taxes~~tax ~~under ASC~~provision ~~740, “Income~~for ~~Taxes.” Under~~ the ~~asset~~periods ~~and~~ended ~~liability~~May ~~method of ASC 740~~31, ~~deferred~~2019 ~~tax assets~~ and ~~liabilities~~ ~~are~~2018, ~~recorded~~consists ~~based on the differences between the financial statement and tax basis~~ of ~~assets and liabilities and~~ the ~~tax~~ rates in effect when these differences are expected to reverse. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations.following:

The income tax provision for the periods ended February 28, 2019 and 2018, consists of the following:

	May 31,			May 31,
	2019			2018
Net income (loss)	$	198,397		$	(1,186,914	)
Effective tax rate		21	%		21	%
Income tax expense (benefit)		41,663			(249,252	)
Less: valuation allowance		(41,663	)		249,252
Income tax expense (benefit)	$	-		$	-

	February 28,			February 28,
	2019			2018
Net income (loss)	$	209,039		$	(567,914	)
Effective tax rate		21	%		21	%
Income tax expense (benefit)		43,898			(119,262	)
Less: valuation allowance		(43,898	)		119,262
Income tax expense (benefit)	$	-		$	-

Net deferred tax assets consist of the following components as of May 31, 2019 and August 31, 2018:

Net deferred tax assets consist of the following components as of February 28, 2019 and August 31, 2018:

	May 31,			August 31,
	2019			2018
Net operating tax carryforwards	$	2,114,989		$	2,156,652
Valuation allowance		(2,114,989	)		(2,156,652	)
Net deferred tax asset	$	-		$	-

	February 28,			August 31,
	2019			2018
Net operating tax carry forwards	$	2,112,754		$	2,156,652
Valuation allowance		(2,112,754	)		(2,156,652	)
Net deferred tax asset	$	-		$	-

On December 22, 2017, the United States enacted the Tax Cuts and Jobs Act (the “Act”) resulting in significant modifications to existing law including lowering the corporate tax rate from 34% to 21%. In addition to applying the new lower corporate tax rate in 2018 and thereafter to any taxable income we may have, the legislation affects the way we can use and carry forward net operating losses previously accumulated and results in a revaluation of deferred tax assets and liabilities recorded on our balance sheet. The Company has completed the accounting for the effects of the Act during the period ended May 31, 2019. Given that current deferred tax assets are offset by a full valuation allowance, these changes will have no impact on the balance sheet.

OnAs ~~December~~of 22May 31, ~~2017~~2019, the ~~United~~Company ~~States~~had ~~enacted~~approximately ~~the~~$10,071,376 ~~Tax~~of ~~Cuts~~net ~~and~~operating ~~Jobs~~loss ~~Act~~ (~~the~~ “~~Act~~NOL”) ~~resulting in~~carry significant modifications to existing law including lowering the corporate tax rate from 34% to 21%. In addition to applying the new lower corporate tax rate in 2018 and thereafter to any taxable income we may haveforwards, the ~~legislation affects the way we can use and carry forward net operating losses previously accumulated and results in a revaluation of deferred~~ tax ~~assets~~effect ~~and liabilities recorded on our balance sheet. The Company has completed the accounting for the effects~~ of ~~the~~which ~~Act~~is ~~during~~approximately ~~the period ended February 28~~$2, ~~2019~~114,989. ~~Given~~These ~~that~~carry ~~current~~forwards ~~deferred~~begin ~~tax~~to ~~assets~~expire ~~are~~in ~~offset by a full valuation allowance, these changes will have no impact on the balance sheet~~2029.

AsThe ofNOL ~~February~~carry ~~28,~~forwards ~~2019,~~are subject to certain limitations due to the change in control of the Company ~~had~~pursuant ~~approximately~~to ~~$10,060,734~~Internal ofRevenue ~~net~~Code ~~operating~~Section ~~loss~~382. ~~(“NOL”) carry~~The ~~forwards,~~Company ~~the~~experienced a change in control for tax ~~effect~~purposes ofin ~~which~~November is2018 ~~approximately~~(see ~~$2,122,754~~Note 1). ~~These~~The Company has not performed a study to determine if the NOL carry forwards ~~begin~~are subject to ~~expire~~these inSection ~~2029~~382 limitations.

~~The~~F-11 ~~NOL~~Table ~~carry forwards are subject to certain limitations due to the change in control~~ of the Company pursuant to Internal Revenue Code Section 382. The Company experienced a change in control for tax purposes in November 2018 (see Note 1). The Company has not performed a study to determine if the NOL carry forwards are subject to these Section 382 limitations.Contents

NOTE 7 - EARNING (LOSS) PER SHARE

The following is a reconciliation of the numerator and denominator used in the basic and diluted earnings per share ("EPS") calculations.

	Three Months Ended						~~Six~~Nine Months Ended
	February 28,						February 28,
	May 31,						May 31,
	2019			2018			2019		2018
Numerator:
Net income (loss)	$	(10,~~972~~642	)	$	(~~409~~619,~~808~~000	)	$	~~209~~198,~~039~~397	$	(~~567~~1,186,914	)
Earnings allocated to participating securities		-			-			-		-
Income (loss) available to common stockholders	$	(10,~~972~~642	)	$	(~~409~~619,~~808~~000	)	$	~~209~~198,~~039~~397	$	(~~567~~1,186,914	)
Denominator:
Weighted-average shares of common stock		49,170,472			49,170,472			49,170,472		49,~~073~~106,~~250~~134
Dilutive effect of convertible instruments		-			-			~~204~~104,~~394~~435,~~490~~141		-
Diluted weighted-average of common stock		49,170,472			49,170,472			~~253~~153,~~564~~605,~~962~~613		49,~~073~~106,~~250~~134
Net income (loss) per common share from:
Basic:	$	(0.00	)	$	(0.01	)	$	0.00	$	(0.0102	)
Diluted:	$	(0.00	)	$	(0.01	)	$	0.00	$	(0.0102	)

For the three months ended ~~February~~May 2831, 2019 and periods ended ~~February~~May 2831, 2018, the convertible instruments are anti-dilutive and therefore, have been excluded from earnings (loss) per share.

For the ~~six~~nine months ended ~~February~~May 2831, 2019, diluted earnings per share is calculated using net income available to common stockholders divided by the diluted weighted average number of common shares outstanding during each period determined using the if-converted method.

NOTE 8 - SUBSEQUENT EVENTS

Management has evaluated subsequent events through the date these financial statements were available to be issued. Based on our evaluation no material events have occurred that require disclosure.

~~F-11~~3 Table of Contents

~~ITEM~~ Item 2. ~~MANAGEMENT~~Management’Ss ~~DISCUSSION~~Discussion ~~AND~~and ~~ANALYSIS~~Analysis OFof ~~FINANCIAL~~Financial ~~CONDITION~~Condition ~~AND~~and ~~RESULTS~~Results OFof ~~OPERATIONS.~~Operations

~~References to~~FORWARD-LOOKING the “Company,” “us,” “our” or “we” refer to Entest Group, Inc. The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed financial statements and related notes included herein.STATEMENTS

~~CERTAIN FORWARD~~This quarterly report contains forward-~~LOOKING~~looking ~~INFORMATION~~statements. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expects”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “potential” or “continue” or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

~~Information provided~~Our inunaudited ~~this~~financial ~~Quarterly report on Form 10Q may contain forward-looking~~ statements ~~within~~are ~~the~~prepared ~~meaning~~in ofaccordance ~~Section~~with ~~21E~~United orStates ~~Securities Exchange~~Generally ~~Act~~Accepted ofAccounting ~~1934 that are not historical facts and information~~Principles. ~~These~~The ~~statements~~following ~~represent~~discussion ~~the~~should ~~Company’s~~be ~~expectations or~~read ~~beliefs,~~in ~~including,~~conjunction ~~but~~with ~~not~~our ~~limited~~financial ~~to,~~ statements ~~concerning future~~ and ~~operating results, statements concerning industry performance,~~ the ~~Company’s operations, economic performance, financial conditions, margins and growth in sales of the Company’s products, capital expenditures, financing needs, as well assumptions~~ related tonotes ~~the~~that ~~forgoing.~~appear ~~For~~elsewhere ~~this purpose, any statements contained~~ in this ~~Quarterly~~quarterly ~~Report~~report. ~~that~~The ~~are~~following ~~not~~discussion ~~statement~~contains ~~of historical fact may be deemed to be~~ forward-looking statements. ~~These forward-looking~~that ~~statements~~reflect ~~are~~our ~~based~~plans, onestimates ~~current expectations~~ and ~~involve~~beliefs. ~~various~~Our ~~risks~~actual ~~and~~results ~~uncertainties that~~ could ~~cause actual results and outcomes for future periods to~~ differ materially from ~~any~~those ~~forward-looking~~discussed ~~statement~~in ~~or views expressed herein. The Company’s financial performance and~~ the forward-looking statements. ~~contained~~Factors ~~herein~~that ~~are~~could ~~further~~cause ~~qualified~~or bycontribute ~~other risks including those set forth from time~~ to ~~time~~such indifferences ~~the~~include, ~~documents~~but ~~filed~~are bynot ~~the~~limited ~~Company with the SEC~~to, ~~including~~those ~~the~~discussed ~~Company’s Annual~~below ~~Report~~and onelsewhere ~~Form~~in ~~10-K~~this ~~for~~quarterly ~~the year ended August 31, 2018~~report.

~~Overview~~In this quarterly report, unless otherwise specified, all dollar amounts are expressed in United States dollars and all references to “common shares” refer to the common shares in our capital stock.

~~The Company~~As ~~currently~~used ~~does~~in ~~not~~this ~~have~~quarterly ~~any~~report, ~~operations and has not actively conducted any operations for~~ the ~~quarter~~terms ~~ended~~“we”, ~~February~~“us”, 28“our”, ~~2019.~~ ~~The~~“our ~~Company’s~~company” ~~business plan for the next 12 months~~ and ~~beyond such time is to seek new business opportunities or to engage in a business combination with an unidentified company. The analysis of new business opportunities will be undertaken by or under~~ “the ~~supervision of the~~ Company’s” ~~management.~~mean AsEntest ~~of the date of this filing~~Group, the Company has not entered into any definitive agreement with any party, nor have there been any specific discussions with any potential business combination candidate regarding business opportunities for the CompanyInc. ~~There can be no assurance that the Company will be able to identify and acquire any business entity. Even if we successfully acquire~~ a ~~business~~Nevada ~~entity~~Company, ~~there~~unless isotherwise ~~no assurance that we can generate revenue and become profitable~~indicated.

~~Results of~~General ~~Operations~~ Overview

~~The Company~~We ~~has~~were ~~not~~incorporated ~~conducted~~in ~~any~~the ~~active~~State ~~operations~~of ~~during~~Nevada ~~the~~on ~~quarter~~September ~~ended February 28~~24, ~~2019.~~2008 Noas ~~revenue~~JB ~~has~~Clothing ~~been generated by the Company within such period~~Corporation. ItUntil isJuly ~~unlikely~~10, ~~the Company will have any revenues unless it is able to effect an acquisition or merger with an operating company~~2009, ofour ~~which~~principal ~~there~~business ~~can~~objective bewas ~~no assurance. It is management’s assertion that these circumstances may hinder~~ the ~~Company’s~~offering ~~ability to continue as a going concern. The Company’s plan~~ of ~~operation~~active/leisure ~~for~~fashion ~~the~~design ~~next twelve months shall be to locate suitable acquisition candidates~~clothing.

~~For~~ On July 10, 2009 the ~~three~~Company ~~months~~abandoned ~~ended~~its ~~February~~efforts ~~28,~~in ~~2019~~the ~~compared~~field ~~with~~of active/leisure fashion design clothing when we acquired 100% of the ~~three~~share ~~months~~capital of Entest BioMedical, Inc., a California corporation. During the quarter ended ~~February~~November 2830, 2018, the Company divested itself of Entest BioMedical, Inc.

The ~~following~~ ~~summary~~Company ofchanged ~~our~~its ~~results~~name ofto ~~operations~~Entest ~~should~~Group, beInc. ~~read~~on ~~in conjunction with our financial statements for the three months ended~~ February ~~2019~~12, ~~which are included herein~~2018.

3Our business and corporate address is No. 911 Bao’an Book City Xinqiao Street Central Road, Bao’an District, Shenzhen, China. We do not have a corporate website.

~~Our operating~~We ~~results~~do ~~for~~not ~~the~~have ~~three~~any ~~months ended February 28, 2019 and the three months ended February 28, 2018 and the changes between those periods for the respective items are summarized as follows:~~subsidiaries.

	Three Months Ended
	February 28,
	2019		2018		Changes ($)
Operating Expenses	$	10,972	$	424,610	$	(413,638	)
Other Income	$	-	$	14,802	$	(14,802	)
Net loss	$	10,972	$	409,808	$	(398,836	)

We have never declared bankruptcy, been in receivership, or involved in any kind of legal proceeding.

~~The Company~~Our ~~has~~Current ~~not conducted any operations during the three months ended February 28, 2019. Revenues from operations were $0 for the three months ended February 28, 2019 and 2018.~~Business

~~For the~~The ~~three~~Company ~~months~~currently does not have any operations and has not actively conducted any operations for the quarter ended ~~February~~May 2831, 2019,. ~~operating~~The ~~expenses~~Company’s business plan for the next 12 months and beyond such time is to seek new business opportunities or to engage in a business combination with an unidentified company. The analysis of ~~$10,972,~~new ~~consisted~~business opportunities will be undertaken by or under the supervision of ~~professional~~the ~~fees~~Company’s management. As of $6the date of this filing,~~395,~~ ~~general~~the ~~and administrative~~Company ~~expenses~~has ofnot $4entered into any definitive agreement with any party,~~577~~ ~~and~~nor ~~other~~have ~~income~~there been any specific discussions with any potential business combination candidate regarding business opportunities for the Company. There can be no assurance that the Company will be able to identify and ~~expenses~~acquire ofany ~~$0,~~business ~~resulting~~entity. inEven aif ~~net~~we ~~loss~~successfully ofacquire ~~$10~~a business entity,~~972~~ there is no assurance that we can generate revenue and become profitable.

~~For the~~4 ~~three~~Table ~~months ended February 28, 2018, operating expenses~~ of $424,610, consisted of professional fees of $84,091, general and administrative expenses of $50,519, and research and development expenses of $290,000. The other income of $14,802 was attributable to rental income of $15,000 and interest expense of $198. Net loss for three months ended February 28, 2018 was $409,808.Contents

~~The decrease~~Results ~~in net loss for the three months ended February 28, 2019, as compared to the same period ended February 28, 2018, was primarily due to the ceasing~~ of ~~prior operations, disposition of subsidiaries and change of control during the first quarter ended November 30, 2018.~~Operations

~~For the~~The ~~six~~Company ~~months~~has not conducted any active operations during the quarter ended ~~February~~May 2831, 2019. ~~compared~~No revenue has been generated by the Company within such period. It is unlikely the Company will have any revenues unless it is able to effect an acquisition or merger with an operating company, of which there can be no assurance. It is management’s assertion that these circumstances may hinder the ~~six~~Company’s ability to continue as a going concern. The Company’s plan of operation for the next twelve months ~~ended~~shall ~~February~~be ~~28,~~to ~~2018~~locate suitable acquisition candidates.

~~Our operating~~For ~~results for~~ the ~~six~~three months ended ~~February~~May 2831, 2019 ~~and~~compared with the ~~six~~three months ended ~~February~~May 2831, 2018 ~~and the changes between those periods for the respective items are summarized as follows:~~

	Six Months Ended
	February 28,
	2019		2018			Changes ($)
Operating Expenses	$	25,026	$	597,382		$	(572,356	)
Other Income	$	234,065	$	29,468		$	204,597
Net Income (Loss)	$	209,039	$	(567,914	)	$	776,953

The following summary of our results of operations should be read in conjunction with our financial statements for the three months ended May 31, 2019, which are included herein.

~~The Company~~Our ~~has~~operating ~~not~~results ~~conducted~~for ~~any~~the ~~operations~~three ~~during~~months ended May 31, 2019 and the ~~six~~three months ended ~~February~~May 2831, ~~2019.~~2018 ~~Revenues~~and ~~from~~the ~~operations~~changes ~~were~~between $0those periods for the ~~six~~ ~~months~~respective ~~ended~~items ~~February~~are ~~28,~~summarized ~~2019~~as ~~and 2018~~follows:

For the six months ended February 28, 2019, operating expenses of $25,026, consisted of professional fees of $8,834 and general and administrative expenses of $16,192.

	Three Months Ended
	May 31,
	2019		2018			Changes ($)
Operating expenses	$	10,642	$	633,639		$	(622,997	)
Other (Income) Expense	$	-	$	(14,639	)	$	14,639
Net Loss	$	10,642	$	619,000		$	(608,358	)

~~For the~~The ~~six~~Company ~~months~~has ~~ended~~not ~~February~~conducted ~~29,~~any ~~2019,~~operations ~~other~~during ~~income~~the ofthree ~~$234,065,~~months ~~consisted~~ended ofMay ~~a gain on write off accounts payables of $23~~31,~~629, gain~~ ~~on disposition of Zander Therapeutics, Inc~~2019. ofRevenues ~~$188,589,~~from ~~rental~~operations ~~income~~were of $~~28,000,~~0 ~~loss~~for onthe ~~disposition~~three ofmonths ~~Entest~~ended ~~Biomedical Inc.~~May ~~of $6~~31,~~947~~ 2019 and ~~interest expense of $495~~2018.

~~The net~~For ~~profit for~~ the ~~six~~three months ended ~~February~~May 2831, 2019, ~~was~~operating expenses of $~~209~~10,~~039~~642, consisted of professional fees of $8,205, general and administrative expenses of $2,437, resulting in a net loss of $10,642.

For the ~~six~~three months ended ~~February~~May 2831, 2018, operating expenses of $~~597~~633,~~382~~639, consisted of professional fees of $~~208~~80,~~190~~980, general and administrative expenses of $9993,~~192~~075, and research and development expenses of $~~290~~459,584. The other income of $14,639 was attributable to rental income of $15,000 and less interest expense of $361. Net loss for three months ended May 31, 2018 was $619,000.

4The decrease in net loss for the three months ended May 31, 2019, as compared to the same period ended May 31, 2018, was primarily due to the ceasing of prior operations, disposition of subsidiaries and change of control during the first quarter ended November 30, 2018.

~~For the~~5 ~~six~~Table ~~months ended February 28, 2018, other income~~ of ~~$29,468 consisted of rental income of $30,000 and interest expenses of $532.~~Contents

~~The net~~For ~~loss for~~ the ~~six~~nine months ended ~~February~~May 2831, ~~2018,~~2019 ~~was~~compared ~~$567~~with the nine months ended May 31,~~914.~~ 2018

~~The increase~~Our inoperating ~~net~~results ~~income~~ for the ~~six~~nine months ended ~~February~~May 2831, 2019, asand ~~compared to~~ the ~~same~~nine ~~period~~months ended ~~February~~May 2831, 2018, ~~was primarily~~and ~~due to other income realized, from~~ the ~~ceasing~~changes ofbetween ~~prior~~those ~~operations,~~periods ~~disposition~~for ~~of subsidiaries and change of control during~~ the ~~first~~respective ~~quarter~~items ~~ended~~are ~~November~~summarized ~~30,~~as ~~2018.~~follows:

Liquidity and Capital Resources

	Nine Months Ended
	May 31,
	2019			2018			Changes ($)
Operating expenses	$	35,668		$	1,231,021		$	(1,195,353	)
Other (Income) Expense	$	(234,065	)	$	(44,107	)	$	(189,958	)
Net Income (Loss)	$	198,397		$	(1,186,914	)	$	1,385,311

~~Working Capital~~The Company has not conducted any operations during the nine months ended May 31, 2019. Revenues from operations were $0 for the nine months ended May 31, 2019 and 2018

	February 28, 2019			August 31, 2018			Changes ($)
Cash	$	-		$	267		$	(267	)
Working capital deficiency	$	(15,250	)	$	(245,711	)	$	230,461
Current and total assets	$	1,040		$	9,307		$	(8,267	)
Current and total liabilities	$	16,290		$	255,018		$	(238,728	)
Total stockholders’ equity (deficit)	$	(15,250	)	$	(245,711	)	$	230,461

For the nine months ended May 31, 2019, operating expenses of $35,668, consisted of professional fees of $17,039 and general and administrative expenses of $18,629.

~~The decrease~~For ~~in working capital deficit was primarily attributed to decreased liabilities from~~ the ~~disposition~~nine ofmonths ~~prior operations~~ended ~~and~~May ~~the change of control occurred in November 2018. As of February 28~~31, 2019, ~~our~~other ~~liabilities~~income ~~decreased~~of $~~238~~234,~~728~~065, ~~from~~ ~~$255,018,~~consisted as of ~~August 31, 2018, to $16,290. The decrease is liabilities is attributable to~~ a ~~decrease~~gain inon ~~notes~~write ~~payable of~~off ~~$19,601, a decrease~~ of accounts payable ~~and accrued liabilities~~ of $~~207~~23,~~677~~629, ~~and~~gain aon ~~decrease~~disposition of ~~unearned~~Zander ~~rental income of $17~~Therapeutics,~~000~~ Inc. As of ~~February 28~~$188, ~~2019~~589, ~~our~~rental ~~current~~income ~~assets~~of ~~decreased~~ $828,~~267~~000, ~~from~~loss ~~$9,307,~~on asdisposition of ~~August~~Entest ~~31,~~Biomedical ~~2018, to $1,040~~Inc. ~~The~~ ~~decrease~~of ~~is primarily attributed to the~~ $86,~~000~~947 inand ~~prepaid~~interest ~~expenses~~expense atof ~~August 31, 2018~~$495.

~~Cash Flows~~The net profit for the nine months ended May 31, 2019 was $198,397.

	Six Months Ended
	February 28,
	2019			2018
Cash Flows used in Operating Activities	$	(3,959	)	$	(744,618	)
Cash Flows used in Investing Activities	$	1,937		$	-
Cash Flows provided by Financing Activities	$	1,755		$	1,400,000
Net Change in Cash During Period	$	(267	)	$	655,382

For the nine months ended May 31, 2018, operating expenses of $1,231,021, consisted of professional fees of $289,170, general and administrative expenses of $192,267 and research and development expenses of $749,584.

~~Cash Flow~~For ~~from~~the ~~Operating~~nine ~~Activities~~months ended May 31, 2018, other income of $44,107 consisted of rental income of $45,000 rental income, interest income of $132 and interest expenses of $1,025.

The net ~~cash~~loss ~~used in operating activities~~ for the ~~six~~nine months ended ~~February~~May 2831, ~~2019~~2018, was ~~attributed to a net profit of~~ $~~209~~1,~~039~~186, increased due to an increase in expenses paid by a related party of $5,550 and loss on disposition of Entest Biomedical of $6,947, and decreased by gain on write off of accounts payable of $23,629, gain on disposition of Zander of $188,589 and a net change in operating assets and liabilities of $13,277914.

The ~~net~~ ~~cash~~increase ~~used~~ in ~~operating~~net ~~activities~~income for the ~~six~~nine months ended ~~February~~May 2831, 2019, as compared to the same period ended May 31, 2018, was ~~attributed~~primarily due to aother ~~net~~income ~~loss~~realized, from the ceasing of ~~$567~~prior operations,~~914,~~ ~~increased by~~disposition aof ~~net~~subsidiaries and change inof ~~operating~~control ~~assets~~during ~~and~~the ~~liabilities~~first ofquarter ~~$176~~ended November 30,~~704~~ 2018.

~~Cash Flow~~Liquidity ~~from~~and ~~Investing~~Capital ~~Activities~~Resources

~~Net~~Working ~~cash from investing activities was $1,937, for the six months ended February 28, 2019, derived from proceeds from a net cash received for divestiture of Entest Biomedical.~~Capital

We did not use any funds for investing activities during the six months ended February 28, 2018.

	May 31, 2019			August 31, 2018			Changes ($)
Cash	$	-		$	267		$	(267	)
Working capital deficiency	$	(25,892	)	$	(245,711	)	$	219,819
Total assets	$	1,040		$	9,307		$	(8,267	)
Total liabilities	$	26,932		$	255,018		$	(228,086	)
Total stockholders’ deficit	$	(25,892	)	$	(245,711	)	$	219,819

5The decrease in working capital deficit was primarily attributed to decreased liabilities from the disposition of prior operations and the change of control occurred in November 2018. As of May 31, 2019, our liabilities decreased $228,086, from $255,018, as of August 31, 2018, to $26,932. The decrease is liabilities is attributable to a decrease in notes payable of $19,601, a decrease of accounts payable and accrued liabilities of $205,112, and a decrease of unearned rental income of $17,000. As of May 31, 2019, our current assets decreased $8,267, from $9,307, as of August 31, 2018, to $1,040. The decrease is primarily attributed to the $8,000 in prepaid expenses at August 31, 2018.

~~Cash Flow~~6 ~~from~~Table ~~Financing~~of ~~Activities~~Contents

~~Net cash~~Cash from financing activities was $1,755, for the six months ended February 28, 2019, derived from proceeds from additional paid in capital offset by bank overdraft, compared to net cash from financing activities of $1,400,000, for the six months ended February 28, 2018, derived from proceeds from common stock issued from subsidiary.Flows

As of February 28, 2019 and August 31, 2018, we had cash of $0 and $267, respectively.

	Nine Months Ended
	May 31,
	2019			2018			Changes ($)
Cash Flows used in Operating Activities	$	(3,959	)	$	(1,065,585	)	$	1,061,626
Cash Flows Provided by Investing Activities	$	1,937		$	-		$	1,937
Cash Flows provided by Financing Activities	$	1,755		$	1,403,000		$	(1,401,245	)
Net Change in Cash During Period	$	(267	)	$	337,415		$	(337,682	)

~~We believe~~Cash ~~that~~Flow wefrom ~~will~~Operating not be able to satisfy our cash requirements over the next twelve months. The Company seeks to acquire an operating company seeking the perceived advantages of being a publicly held corporation. No assurance can be given that such an acquisition shall occur or, if such an acquisition were to occur, it would occur on terms and conditions beneficial to the Company or its shareholders. The Company is also dependent upon the receipt of capital investment or other financing to fund its ongoing operations and to execute its business plan of seeking a combination with a private operating company. In addition, the Company anticipates that it will be dependent upon certain related parties to provide continued funding and capital resources. If continued funding and capital resources are unavailable at reasonable terms, the Company may not be able to implement its plan of operations.Activities

~~Critical Accounting~~The ~~Policies~~net cash used in operating activities for the nine months ended May 31, 2019 was attributed to a net income of $198,397, increased due to an increase in expenses paid by a related party of $13,627 and ~~Estimates~~loss on disposition of Entest Biomedical of $6,947, and decreased by gain on write off of accounts payable of $23,629, gain on disposition of Zander of $188,589 and a net change in operating assets and liabilities of $10,712.

~~Use~~ The net cash used in operating activities for the nine months ended May 31, 2018 was attributed to a net loss of ~~Estimates~~$1,186,914, decreased by a net change in operating assets and liabilities of $121,329.

~~The preparation~~Cash ofFlow financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at dates of the financial statements and the reported amounts of revenue and expenses during the periods. Actual results could differ from ~~these~~Investing ~~estimates. Our significant estimates and assumptions include depreciation, stock-based compensation and the valuation allowance relating to the Company’s deferred tax assets.~~Activities

~~Recently Issued~~Net ~~Accounting~~cash ~~Pronouncements~~from investing activities was $1,937, for the nine months ended May 31, 2019, derived from proceeds from a net cash received for divestiture of Entest Biomedical.

~~Reference is~~We ~~made~~did tonot ~~the~~use ~~“Recent~~any ~~Accounting~~funds ~~Pronouncements” in Note 2 to the Financial Statements included in this report~~ for ~~information~~ ~~related~~investing toactivities ~~new~~during ~~accounting pronouncement, none of which had a material impact on our consolidated financial statements, and~~ the ~~future~~nine ~~adoption~~months ofended ~~recently~~May ~~issued accounting pronouncements~~31, ~~which we do not expect will have a material impact on our consolidated financial statements~~2018.

~~Off-Balance Sheet~~Cash ~~Arrangements~~Flow from Financing Activities

~~As of~~Net ~~February~~cash 28from financing activities was $1,755, for the nine months ended May 31, 2019, wederived dofrom ~~not~~proceeds ~~have~~from ~~any~~contributed ~~off-balance~~capital ~~sheet~~offset ~~arrangements~~by bank overdraft, compared to net cash from financing activities of $1,403,000, for the nine months ended May 31, 2018, derived from proceeds from common stock issued from subsidiary of $1,400,000 and proceeds from note payable of $3,000.

~~Item 3.~~As ~~Quantitative~~of May 31, 2019 and ~~Qualitative~~August ~~Disclosures~~31, ~~About~~2018, ~~Market~~we ~~Risk~~had cash of $0 and $267, respectively.

We ~~are~~ abelieve ~~smaller~~that ~~reporting~~we ~~company~~will asnot ~~defined~~be byable ~~Rule~~to ~~12b-2~~satisfy ofour cash requirements over the ~~Exchange~~next ~~Act~~twelve ~~and~~months. ~~are~~The ~~not~~Company ~~required~~seeks to ~~provide~~ acquire an operating company seeking the ~~information~~perceived ~~under~~advantages ~~this~~of ~~item~~being a publicly held corporation. WeNo ~~have~~assurance ~~chosen~~can tobe ~~disclose~~given that such an acquisition shall occur or, ~~however~~if such an acquisition were to occur, ~~that~~it wewould ~~have~~occur ~~not~~on ~~engaged~~terms inand ~~any~~conditions ~~transactions,~~beneficial ~~issued~~to the Company or ~~bought~~ ~~any~~its ~~financial~~shareholders. ~~instruments~~The Company is also dependent upon the receipt of capital investment or ~~entered~~other ~~into~~financing ~~any~~to ~~contracts~~fund ~~that~~its ~~are~~ongoing ~~required~~operations and to execute its business plan of seeking a combination with a private operating company. In addition, the Company anticipates that it will be ~~disclosed~~dependent inupon ~~response~~certain related parties to ~~this~~provide ~~item~~continued funding and capital resources. If continued funding and capital resources are unavailable at reasonable terms, the Company may not be able to implement its plan of operations.

~~Item 4.~~Critical ~~Controls~~Accounting Policies and ~~Procedures.~~Estimates

~~Evaluation~~ Use of ~~Disclosure Controls and Procedure.~~Estimates

~~Our management~~The ispreparation ~~responsible for establishing and maintaining a system~~ of ~~disclosure~~financial ~~controls~~statements ~~and procedures (as defined~~ in ~~Rule 13a-15(e)~~conformity ~~under~~with ~~the~~accounting ~~Exchange~~principles ~~Act~~generally ~~that~~accepted ~~is designed to provide reasonable assurance that information we are required to disclose~~ in the ~~reports~~United ~~that~~States weof ~~file~~America orrequires ~~submit~~management ~~under~~to ~~the~~make ~~Exchange~~estimates ~~Act are recorded, processed, summarized~~ and ~~reported,~~assumptions ~~within~~that ~~the~~affect ~~time periods specified in~~ the ~~SEC’s~~reported ~~rules~~amounts ~~and~~of ~~forms.~~assets ~~Disclosure controls~~ and ~~procedure~~liabilities ~~include, without limitations, controls~~ and ~~procedures~~disclosure ~~designed~~of tocontingent ~~ensure~~liabilities ~~that~~at ~~information~~dates ~~required~~of ~~to be disclosed by an issuer in~~ the ~~reports~~financial ~~that~~statements itand ~~files or submits under~~ the ~~Exchange~~reported ~~Act~~amounts isof ~~accumulated~~revenue and ~~communicated~~expenses toduring the ~~issuer’s~~periods. ~~management,~~Actual ~~including~~results ~~its~~could ~~principal~~differ ~~executive~~from ~~officer or~~these ~~officers~~estimates. ~~and~~Our ~~principal~~significant ~~financial~~estimates ~~officer~~and orassumptions ~~officers~~include depreciation, orstock-based ~~persons~~compensation ~~performing~~and ~~similar~~the ~~functions,~~valuation asallowance ~~appropriate~~relating to ~~allow~~the ~~timely decisions~~Company’s ~~regarding~~deferred ~~required~~tax ~~disclosure~~assets.

67 Table of Contents

~~Pursuant to~~Recently ~~Rule~~Issued ~~13a-15(b)~~Accounting under the Exchange Act, we carried out an evaluation, under the supervision and with the participation of Peiwen Yu, our Principal Executive Officer/Principal Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Our Principal Executive Officer/Principal Financial Officer has concluded that our disclosure controls and procedures were not effective at this reasonable assurance level as of the period covered by this report.Pronouncements

~~Changes~~ Reference is made to the “Recent Accounting Pronouncements” in ~~Internal~~Note ~~Controls~~2 ~~over~~to the Financial ~~Reporting~~Statements included in this report for information related to new accounting pronouncement, none of which had a material impact on our consolidated financial statements, and the future adoption of recently issued accounting pronouncements, which we do not expect will have a material impact on our consolidated financial statements.

~~In connection~~Off-Balance ~~with~~Sheet the evaluation of the Company’s internal controls during the period commencing on December 1, 2018 and ending on February 28, 2019, Peiwen Yu, the Company’s Principal Executive Officer and Principal Financial Officer has determined that there were no changes to the Company’s internal controls over financial reporting that have been materially affected, or are reasonably likely to materially effect, the Company’s internal controls over financial reporting.Arrangements

~~PART II~~As of May 31, 2019, we do not have any off-balance ~~OTHER~~sheet ~~INFORMATION~~arrangements.

Item 1 3. ~~Legal~~Quantitative ~~Proceedings.~~and Qualitative Disclosures About Market Risk

~~None~~As a “smaller reporting company”, we are not required to provide the information required by this Item.

Item 1A 4. ~~Risk~~Controls ~~Factors.~~and Procedures

~~We are~~Evaluation ~~a smaller reporting company as defined by Rule 12b-2~~ of ~~the~~Disclosure ~~Exchange~~Controls ~~Act~~ and ~~are not required to provide the information under this item.~~Procedures

~~Item 2.~~Our ~~Unregistered~~management ~~Sales~~is ofresponsible ~~Equity~~for ~~Securities~~establishing and ~~Use~~maintaining a system of ~~Proceeds~~disclosure controls and procedures (as defined in Rule 13a-15(e) under the Exchange Act that is designed to provide reasonable assurance that information we are required to disclose in the reports that we file or submit under the Exchange Act are recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedure include, without limitations, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management, including its principal executive officer or officers and principal financial officer or officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

~~None~~Pursuant to Rule 13a-15(b) under the Exchange Act, we carried out an evaluation, under the supervision and with the participation of Peiwen Yu, our Principal Executive Officer/Principal Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Our Principal Executive Officer/Principal Financial Officer has concluded that our disclosure controls and procedures were not effective at this reasonable assurance level as of the period covered by this report.

~~Item 3.~~Changes ~~Defaults~~in ~~Upon~~Internal ~~Senior Securities~~Controls

~~None~~There have been no changes in our internal controls over financial reporting identified in connection with the evaluation required by paragraph (d) of Securities Exchange Act Rule 13a-15 or Rule 15d-15 that occurred in the quarter ended May 31, 2019 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

~~Item 4.~~8 ~~Mine~~Table ~~Safety~~of ~~Disclosures~~Contents

~~Not applicable.~~PART II - OTHER INFORMATION

Item 5 1. ~~Other~~Legal ~~Information~~Proceedings

~~None~~From time to time, we may become involved in litigation relating to claims arising out of its operations in the normal course of business. We are not involved in any pending legal proceeding or litigation and, to the best of our knowledge, no governmental authority is contemplating any proceeding to which we area party or to which any of our properties is subject, which would reasonably be likely to have a material adverse effect on us.

7Item 1A. Risk Factors

As a “smaller reporting company”, we are not required to provide the information required by this Item 6. ~~Exhibits~~

~~(a) Exhibits~~Item ~~required~~2. byUnregistered ~~Item~~Sales ~~601~~ of ~~Regulation~~Equity ~~S-K.~~Securities and Use of Proceeds

Exhibit		Description
31.1		Certification of the Company’s Principal Executive Officer and Principal Financial and Accounting Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, with respect to the registrant’s Quarterly Report on Form 10-Q for the quarter ended February 28, 2019.
32.1		Certification of the Company’s Principal Executive Officer and Principal Financial and Accounting Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Extension Schema Document
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document.
101.LAB		XBRL Taxonomy Extension Label Linkbase Document.
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document.
101.DEF		XBRL Taxonomy Extension Definition Linkbase Document.

None.

~~SIGNATURE~~Item 3. Defaults Upon Senior Securities

~~Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized~~None.

		ENTEST GROUP, INC.
Dated: April 29, 2019	By:	/s/ Peiwen Yu
		Peiwen Yu
		Title: Chief Executive Officer and President (Principal Executive officer, and Principal Financial and Accounting Officer)

Item 4. Mine Safety Disclosures

8Not Applicable.

Item 5. Other Information

None.

Item 6. Exhibits

Exhibit Number		Description
(31)		Rule 13a-14 (d)/15d-14d) Certifications
31.1*		Section 302 Certification by the Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer
(32)		Section 1350 Certifications
32.1*		Section 906 Certification by the Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer
101*		Interactive Data File
101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Extension Schema Document
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		XBRL Taxonomy Extension Label Linkbase Document
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

____________

* Filed herewith.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		Entest Group, Inc.
		(Registrant)

Dated: July 15, 2019		/s/ Peiwen Yu
		Peiwen Yu
		Chief Executive Officer and President
		(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)

Filing Compare · ENTEST GROUP, INC.